Genfleet Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 159

Employees

  • Stock Symbol
  • 02595

Stock Symbol

  • Share Price
  • $2.76
  • (As of Friday Closing)

Genfleet General Information

Description

GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.

Contact Information

Website
www.genfleet.com
Formerly Known As
Jinfang Pharmaceutical Technology (Shanghai), Jingfang Pharmaceutical (Shanghai)
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Building A, Zhangjiang MOTOR Science and Technology Park
  • Number 1206 Zhangjiang Road, Pudong New Area
  • Shanghai, 201203
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
HKG
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Building A, Zhangjiang MOTOR Science and Technology Park
  • Number 1206 Zhangjiang Road, Pudong New Area
  • Shanghai, 201203
  • China
+86 021

Genfleet Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genfleet Stock Performance

As of 13-Nov-2026, Genfleet’s stock price is $2.76. Its current market cap is $1.05B with 381M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.76 $3.04 $2.24 - $6.75 $1.05B 381M 3.14M -$0.65

Genfleet Financials Summary

As of 30-Jun-2026, Genfleet has a trailing 12-month revenue of $12M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,110,644 1,095,588
Revenue 12,004 18,114 14,592 10,422
EBITDA (194,223) (251,610) (94,020) (70,637)
Net Income (188,085) (249,541) (94,439) (71,849)
Total Assets 285,560 313,805 83,125 75,633
Total Debt 20,428 14,424 9,500 4,468
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Genfleet Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Genfleet‘s full profile, request access.

Request a free trial

Genfleet Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries
Drug Discovery
Shanghai, China
159 As of 2026

Tuebingen, Germany
 

Suzhou, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genfleet Competitors (13)

One of Genfleet’s 13 competitors is Immatics, a Formerly VC-backed company based in Tuebingen, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immatics Formerly VC-backed Tuebingen, Germany
Alphamab Oncology Formerly VC-backed Suzhou, China
Abbisko Medicine Formerly VC-backed Shanghai, China
GenScript Formerly VC-backed Nanjing, China
EMD Serono Corporation Boston, MA
You’re viewing 5 of 13 competitors. Get the full list »

Genfleet Patents

  • 161

    Total Documents Applications and Grants

  • Total Patents Families

  • 59

    Granted

  • 50

    Pending

  • Expiring in next 12 mo

Genfleet Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026124629-A1 Heterocyclic compound, preparation method therefor, and use thereof Pending 13-Dec-2024
WO-2026067753-A1 Macrocyclic compound and preparation method therefor and use thereof Pending 29-Sep-2024
WO-2026041084-A1 Antibody or antibody-drug conjugate Pending 21-Aug-2024
WO-2026026967-A1 Acryloyl compound and use thereof Pending 02-Aug-2024
WO-2025223473-A1 Anti-gdf-15 antibody and use thereof Pending 23-Apr-2024
To view Genfleet’s complete patent history, request access »

Genfleet Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genfleet Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Genfleet‘s full profile, request access.

Request a free trial

Genfleet ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Genfleet’s complete esg history, request access »

Genfleet FAQs

  • When was Genfleet founded?

    Genfleet was founded in 2017.

  • Where is Genfleet headquartered?

    Genfleet is headquartered in Shanghai, China.

  • What is the size of Genfleet?

    Genfleet has 159 total employees.

  • What industry is Genfleet in?

    Genfleet’s primary industry is Drug Discovery.

  • Is Genfleet a private or public company?

    Genfleet is a Public company.

  • What is Genfleet’s stock symbol?

    The ticker symbol for Genfleet is 02595.

  • What is the current stock price of Genfleet?

    As of 13-Nov-2026 the stock price of Genfleet is $2.76.

  • What is the current market cap of Genfleet?

    The current market capitalization of Genfleet is $1.05B.

  • What is Genfleet’s current revenue?

    The trailing twelve month revenue for Genfleet is $12M.

  • Who are Genfleet’s competitors?

    Immatics, Alphamab Oncology, Abbisko Medicine, GenScript, and EMD Serono are some of the 13 competitors of Genfleet.

  • What is Genfleet’s annual earnings per share (EPS)?

    Genfleet’s EPS for 12 months was -$0.65.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process